Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cerecor (CERC) Stock Price

Media stories about Cerecor (NASDAQ:CERC) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerecor earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.3783141044037 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Cerecor (NASDAQ:CERC) traded up $0.38 during midday trading on Wednesday, hitting $2.55. The stock had a trading volume of 2,367,600 shares, compared to its average volume of 563,421. The firm has a market capitalization of $56.54, a price-to-earnings ratio of 217.00 and a beta of 2.99. Cerecor has a 52 week low of $0.34 and a 52 week high of $2.83.

CERC has been the topic of a number of research analyst reports. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.

In other news, major shareholder Armistice Capital Master Fund acquired 45,200 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $54,240.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Armistice Capital, Llc acquired 35,200 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were purchased at an average price of $1.20 per share, with a total value of $42,240.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 130,980 shares of company stock worth $142,753. 10.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cerecor (CERC) Stock Price” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/12/20/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cerecor-cerc-stock-price.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit